SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is rallying as investors react to record revenue growth and the company's first-ever positive operating cash flow, signaling a pivotal shift toward profitability. The community is actively debating the sustainability of this momentum, weighing long-term conviction in their semiconductor-based ultrasound technology against concerns regarding historical share dilution and potential resistance levels.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to develop solid-state battery technology and manufacturing processes, fueling investor optimism regarding long-term scaling potential. The community is actively debating the significance of this OEM validation versus the need for more concrete commercialization timelines, while keeping a close eye on upcoming earnings and potential future partner announcements.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense community debate as investors react to its aggressive Bitcoin-linked financial strategy amid cooling crypto market conditions. Shareholders are actively discussing concerns over company debt and dilution, while bulls and bears clash over the long-term viability of the firm's leveraged exposure to Bitcoin.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant investor attention as its oral Wegovy tablet continues to exhibit rapid adoption, with new weekly prescriptions outpacing competitor GLP-1 pills. The community remains focused on whether this oral growth can offset competitive pressure from Eli Lilly and broader sector volatility, while analysts continue to adjust valuation models amid strong demand for metabolic treatments.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is attracting heavy investor attention as the market positions it as a critical domestic supplier for the defense, space, and AI infrastructure sectors. Community discussion is currently focused on the company's ultra-precision manufacturing capabilities, its strategic positioning within U.S.-based supply chains, and the high potential for growth linked to LEO satellite and data center optics demand.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is surging following an earnings report that highlighted a major acceleration in AI infrastructure orders, leading the company to raise its guidance and announce a strategic pivot toward high-growth networking segments. The community is actively debating whether this movement represents a legitimate structural re-rating of the stock into a key AI player or a speculative bubble reminiscent of the dot-com era.

TOSHI

TOSHI is trending as the community anticipates potential AI-driven utility announcements and product integrations within the Base ecosystem. Investors are actively discussing the token's role as a prominent cat-themed asset while sharing bullish sentiment regarding recent consolidation patterns and the possibility of a significant breakout.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors debate its role as a defensive safe haven amid broader market volatility and a rotation away from high-valuation tech stocks. The community is actively discussing the stock's potential for a rebound toward previous highs, fueled by expectations surrounding the upcoming shareholder meeting and continued strength in e-commerce and delivery operations despite ongoing economic pressures.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant strengthening of its intellectual property, specifically the listing of a key MIPLYFFA patent in the FDA's Orange Book that extends exclusivity through 2041. The community is actively discussing this bullish catalyst alongside multiple analyst price target upgrades, while also debating the potential timeline for European market authorization and the long-term impact on the company's valuation.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending as retail investors digest a mix of strong operational backlogs and analyst upgrades against ongoing frustration over insider selling and valuation volatility. The community is actively debating the stock's long-term potential in autonomous defense and drone technology versus its recent price declines, with many weighing the impact of institutional positioning and sector-wide consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’

Equity

CFO said at a conference that profitability is “right around the corner,” though the company is waiting for more top-line certainty before formal guidance.


Should You Buy Ardelyx (ARDX)?

Ardelyx (NASDAQ:ARDX) Trading Up 7.4% - What's Next?

Ardelyx (NASDAQ:ARDX) Shares Up 7.4% - What's Next...

FY2030 Earnings Forecast for Ardelyx Issued By HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at HC Wainwright cut their FY2030 earnings per share estimates for Ardelyx in a research note issued on Friday, May 1st. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn $1.60 per share for th...

AIGH Capital Management LLC Purchases 951,500 Shares of Ardelyx, Inc. $ARDX

AIGH Capital Management LLC lifted its position in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 479.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,150,000 shares of the biopharmaceutical company's...

Ardelyx (NASDAQ:ARDX) Shares Gap Down After Earnings Miss

Ardelyx (NASDAQ:ARDX) Shares Gap Down Following Weak Earnings...

Ardelyx (NASDAQ:ARDX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Ardelyx (NASDAQ:ARDX - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus...

Ardelyx (ARDX) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -15.39% and +3.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx Q1 Earnings Call Highlights

Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with "another significant year of growth" underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t...

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ARDXArdelyx Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARDX News